コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 n is shown to inhibit cancer cell growth and tumorigenicity.
2 A methyltransferases for CSC maintenance and tumorigenicity.
3 an important modulator and even a driver of tumorigenicity.
4 in C receptor (EPCR) in MPM cells suppresses tumorigenicity.
5 stic phenotype and contributes to epithelial tumorigenicity.
6 perties, thyrosphere formation, and enhanced tumorigenicity.
7 ion ultimately contributing to LMW-E-induced tumorigenicity.
8 he growth, invasion, migration, stemness and tumorigenicity.
9 ssive properties of hMSC and increased their tumorigenicity.
10 reduced stem marker expression and decreased tumorigenicity.
11 temness with higher angiogenic potential and tumorigenicity.
12 proteins BMI-1 and EZH2, which contribute to tumorigenicity.
13 eactivation of progenitor functions supports tumorigenicity.
14 a mechanism through which DAXX promotes PCa tumorigenicity.
15 in miR-21KD cancer cells restored their high tumorigenicity.
16 crophage ratios may account for the enhanced tumorigenicity.
17 th by coordinately linking immune escape and tumorigenicity.
18 nuated DCA-induced colorectal cancer or PDAC tumorigenicity.
19 latory promoter regions, leading to enhanced tumorigenicity.
20 n connection between CFIm25 and glioblastoma tumorigenicity.
21 a consequence of miR-9 inhibition, increases tumorigenicity.
22 , indicating regulation of proliferation and tumorigenicity.
23 creased cellular senescence, and/or enhanced tumorigenicity.
24 ssion of miR-9 upregulates FOXP1 to increase tumorigenicity.
25 miting oxygen conditions may be required for tumorigenicity.
26 whereas Prep1 overexpression inhibits Meis1 tumorigenicity.
27 by both altering the immunogenicity and the tumorigenicity.
28 ll growth, promigratory characteristics, and tumorigenicity.
29 cancer-specific epigenetic abnormalities on tumorigenicity.
30 to overexpress tissue factor increased their tumorigenicity.
31 n levels of RNAs and of their changes during tumorigenicity.
32 usly and demonstrates for the first time its tumorigenicity.
33 tissue factor did not increase their limited tumorigenicity.
34 gulator of stress responses, metabolism, and tumorigenicity.
35 e the epigenetic drivers causing the loss of tumorigenicity.
36 cers and its levels appear to correlate with tumorigenicity.
37 and selectively reduce mutant PIK3CA-induced tumorigenicity.
38 stic suppression of driver oncogenes and HCC tumorigenicity.
39 tion, single cell clonogenicity, and in vivo tumorigenicity.
40 g to enhanced STAT3 signaling activation and tumorigenicity.
41 in supporting RAS-induced transformation and tumorigenicity.
42 neage bias, proliferation, self-renewal, and tumorigenicity.
43 ion and have been implicated in Ras-mediated tumorigenicity.
44 regulate the induction of stiffness-mediated tumorigenicity.
45 lays compromised kinase activity and reduced tumorigenicity.
46 and/or pharmacological inhibition to reduced tumorigenicity.
47 ment without compromising tumour stemness or tumorigenicity.
48 ion, which is of importance for RAS-mediated tumorigenicity.
49 tion and induced apoptosis but also impaired tumorigenicity.
50 ollutants in Caco-2 cells and increase their tumorigenicity.
51 tumor cells and regulates their stemness and tumorigenicity.
52 induce gene expression programs essential in tumorigenicity.
53 cancer models displaying varying degrees of tumorigenicity.
54 thesis-that is important for prostate cancer tumorigenicity.
55 ing an STF program associated with increased tumorigenicity.
56 red proliferation but increased intracranial tumorigenicity.
58 ed serine protease encoded by suppression of tumorigenicity-14 (ST14) gene, which is critical for epi
59 al motifs [reck; also known as suppressor of tumorigenicity 15 protein (ST15)], which encodes a membr
61 c changes in IL33 and soluble suppression of tumorigenicity 2 (sST2) levels were measured in the plas
62 C motif) ligand 9 (CXCL9) and suppression of tumorigenicity 2 (ST2) also were measured on the basis o
63 the role of the IL-33 receptor suppressor of tumorigenicity 2 (ST2) in the persistence of asthma in a
65 ike 1 (IL1RL1), also known as suppression of tumorigenicity 2 (ST2), is the receptor for interleukin
67 litated tumor regression in a suppression of tumorigenicity 2 receptor (ST2) (IL-33 receptor)-indepen
68 acid-binding protein, soluble suppression of tumorigenicity 2, and lipopolysaccharide were assessed.
70 p < 0.0001) and day 3 soluble suppression of tumorigenicity-2 (median, 7,678 mL [interquartile range,
71 We assayed plasma soluble suppression of tumorigenicity-2 (n = 826) concentrations and interleuki
72 for reintubation for soluble suppression of tumorigenicity-2 (odds ratio, 3.23; 95% CI, 1.04-10.07;
75 ay 0 and day 3 median soluble suppression of tumorigenicity-2 and interleukin-6 concentrations had de
77 We determined whether soluble suppression of tumorigenicity-2 and interleukin-6 levels can be used as
78 We tested whether soluble suppression of tumorigenicity-2 and interleukin-6 levels were associate
79 , interleukin-33, and soluble suppression of tumorigenicity-2 between matched patients who were treat
84 nd interleukin-33 and soluble suppression of tumorigenicity-2) within 24 hours of acute respiratory d
85 urther adjustment for soluble suppression of tumorigenicity-2, elevated Gal-3 remained associated wit
86 75; p < 0.0001; day 3 soluble suppression of tumorigenicity-2: hazard ratio, 0.64; 95% CI, 0.54-0.75;
87 tion over time (day 0 soluble suppression of tumorigenicity-2: hazard ratio, 0.85; 95% CI, 0.72-1.00;
88 eous breathing trial (soluble suppression of tumorigenicity-2: odds ratio, 0.45; 95% CI, 0.28-0.71; p
89 weaning assessments (soluble suppression of tumorigenicity-2: odds ratio, 0.62: 95% CI, 0.44-0.87; p
90 hich is accompanied by a substantial loss of tumorigenicity and a switch from canonical to noncanonic
91 ibits uncontrolled proliferation and reduces tumorigenicity and aggressiveness of HCC cells through R
92 cer cells, influence mammary epithelial cell tumorigenicity and aggressiveness, and increase breast c
93 levels of GHCer displayed relatively greater tumorigenicity and angiogenesis compared with cells expr
94 stable, not consistently linked to increased tumorigenicity and associated with genetic heterogeneity
99 OSIC-like properties of self-renewal, strong tumorigenicity and differentiation to CD49f(+) progeny.
103 e of the side population (SP) and in vivo as tumorigenicity and experimental metastatic potential in
104 Let-7 targets Imp1-3 are required for this tumorigenicity and feed back to reinforce and sustain ex
107 ovel mechanism by which Vav1 can enhance the tumorigenicity and invasive potential of cancer cells.
108 sion of miR-141 is inversely correlated with tumorigenicity and invasiveness in several human cancers
109 indicate the importance of this pathway for tumorigenicity and invasiveness of KDM2A-overexpressing
112 the major role of PTGES/PGE(2) signaling in tumorigenicity and lung metastasis is through immunosupp
113 Because N2P2 has been shown to increase tumorigenicity and M3P6 to decreases it, we sought to de
117 state cancer (PCa) cell migration, invasion, tumorigenicity and metastasis using a human PCa progress
123 riptase activity and significantly decreased tumorigenicity and metastatic capability in orthotopical
124 itochondrial SNPs regulate mammary carcinoma tumorigenicity and metastatic potential in genetic cross
126 of the spliceosome in vivo impairs survival, tumorigenicity and metastatic proclivity of MYC-dependen
128 ivated in TNBC and has a pivotal role in the tumorigenicity and progression of this human breast canc
129 n increased cell motility, invasiveness, and tumorigenicity and provides a valuable model for studyin
131 n hNCPCs(V600E) dramatically increased their tumorigenicity and resulted in fully transformed tumor c
134 yglucose, a glycolysis inhibitor, to reverse tumorigenicity and sorafenib resistance mediated by PRMT
135 B enhances the several phenotypes, including tumorigenicity and sphere-forming ability, which are ind
136 FGFR3 mutations have very limited urothelial tumorigenicity and that these mutations must collaborate
137 ays an integral role in enhancing pancreatic tumorigenicity and the function of cancer stem cells in
138 ay for in vivo evaluation of CTCL cell lines tumorigenicity and therapeutic response in preclinical s
139 ene-expression profiles that could influence tumorigenicity and therapeutic response, and we therefor
140 s, regulation of metastases genes, increased tumorigenicity and was important for BCSC invasion and m
141 ltaEGFR access to the nucleus attenuates its tumorigenicity and, conversely, that promoting nuclear a
142 sed in GSCs, play a key role in glioblastoma tumorigenicity, and are potential therapeutic targets ag
143 aberrant FBP1 expression contributed to CRC tumorigenicity, and decreased FBP1 expression coupled wi
144 the long-term (>5 weeks) effects, potential tumorigenicity, and fate of transplanted CPCs are unknow
146 ifferences in self-renewal, gene expression, tumorigenicity, and metastatic potential of spheres at g
149 associated with increased EGFR activity and tumorigenicity, and we found that Rak/Frk associates pre
151 lanoma-specific PD-1 overexpression enhances tumorigenicity, as does engagement of melanoma-PD-1 by i
154 ed a remarkable increase in self-renewal and tumorigenicity associated with long-lasting gene express
155 contrary to expectations, the mechanisms of tumorigenicity associated with mutations in different ge
156 ted in vivo, we did not find a difference in tumorigenicity between high and low Wnt activity, while
157 , TbetaRIII-SS (EMT) cells exhibit decreased tumorigenicity but increased growth rate in vitro and in
158 NG functions to drive transformed growth and tumorigenicity by activating PKCiota-dependent cell auto
159 atory network revealed that XBP1 drives TNBC tumorigenicity by assembling a transcriptional complex w
160 esults in an increased CSC-like property and tumorigenicity by enhancing the interaction of beta-cate
161 iate into quasi-normal cells with suppressed tumorigenicity by selective inhibition of the MAPK/ERK/M
164 identify OSIC-like cells that possess strong tumorigenicity correlated with an impaired osteogenic fa
166 governs epithelial cell plasticity, EMT, and tumorigenicity during breast cancer initiation and progr
167 ced proliferation, apoptosis resistance, and tumorigenicity, effects rescued by estrogen supplementat
169 D24, ALDH-1, EpCAM, Lgr5), multipotency, and tumorigenicity following injection in immunodeficient mi
170 en adapted for in vivo experiments and their tumorigenicity has not been adequately assessed, hamperi
172 ling regulates cancer cell proliferation and tumorigenicity, Hh inhibitors have the potential to trea
174 carefully monitor for the potential risks of tumorigenicity, immunogenicity, and arrhythmogenicity.
177 ancer cell (TNBC) death in vitro and reduced tumorigenicity in a xenograft TNBC mouse model in vivo.
178 r B (IL-17RB) and its ligand IL-17B promoted tumorigenicity in breast cancer cells and impeded acinus
181 STAT3 signaling, cell-cycle progression, and tumorigenicity in human colorectal cancer and pancreatic
188 cer stem cells in vitro, as well as enhanced tumorigenicity in murine models of primary tumour growth
195 orrelated with chemoresistance and increased tumorigenicity in vitro and in vivo accompanied by incre
198 educed cell proliferation, cell invasion and tumorigenicity in vitro, but also inhibited tumor growth
199 ion, and drug resistance in vitro and higher tumorigenicity in vivo than those constitutively express
200 endometrial cancer cell growth in vitro and tumorigenicity in vivo, as a result of inhibition of cel
201 e adenocarcinoma-like histology in vitro and tumorigenicity in vivo, recapitulating multi-hit models
213 gnaling in cancer cells to promote decreased tumorigenicity, increased immunogenicity, and enhanced i
215 promotes malignant progression of HBECs and tumorigenicity, invasion, and metastases in non-small ce
217 phere-forming ability, and exhibit increased tumorigenicity, known characteristics of cancer stemness
220 e importance of PAR1 to the self-renewal and tumorigenicity of A2B5-defined glioma TPCs; as such, the
221 of A549 lung cancer cells and suppresses the tumorigenicity of A549 cells in severe combined immunode
222 rotein alone, significantly enhances in vivo tumorigenicity of AGS gastric cancer cells and correlate
227 hermore, blocking RSPO signaling reduced the tumorigenicity of cancer cells based on serial transplan
228 ever, the molecular mechanisms promoting the tumorigenicity of cancer cells undergoing an EMT and of
232 transformed cells, we compared the relative tumorigenicity of Cre-LoxP conditional disruption of the
236 whose expression levels directly impact the tumorigenicity of glioblastoma (GBM) in vitro and in viv
238 ase (MAGL), to regulate the self-renewal and tumorigenicity of GSCs through production of prostagland
241 ombination with HER2 inhibitors, reduced the tumorigenicity of HR(-)/HER2(+) breast cancers, opening
242 t studies, we demonstrate that DAXX promotes tumorigenicity of human ALVA-31 and PC3 prostate cancer
243 ibition of glycolysis preferentially impedes tumorigenicity of human lung cancer cells bearing KMT2D-
246 IKBKE-associated cytokine signaling promotes tumorigenicity of immune-driven TNBC and identify a pote
247 that are important for the proliferation and tumorigenicity of KEAP1-mutant non-small cell lung cance
249 N axis synergistically suppresses growth and tumorigenicity of lung cancer cells, our findings may op
252 interference inhibits the proliferation and tumorigenicity of MYCN-amplified neuroblastoma cell line
253 the processed product of p105), inhibits the tumorigenicity of NF-kappaB1-deficient lung tumor cells.
254 IKKalpha induces differentiation and reduces tumorigenicity of NPC cells without activating NF-kappaB
257 FGF18 controlled migration, invasion, and tumorigenicity of ovarian cancer cells through NF-kappaB
260 lifelong phenotype correction and reduce the tumorigenicity of progressive familial intrahepatic chol
261 s, promoted radiosensitization, and hindered tumorigenicity of radioresistant prostate cancer cells.
262 pathway-regulated cofactor YAP1 supports the tumorigenicity of RAS mutations but requires both inacti
263 mately beta) inhibited the proliferation and tumorigenicity of Ras(V12)-transformed NIH 3T3 cells, ac
264 r transformation; however, the importance to tumorigenicity of RNA 3'-end-processing factors that pot
273 er, the V777L mutation did not alter in vivo tumorigenicity or sensitivity to HER2-directed therapies
276 n of cancer cells endowed with self-renewal, tumorigenicity, pluripotency, chemoresistance, different
277 macroH2A1 in bladder cancer cells increased tumorigenicity, radioresistance, degeneration of reactiv
278 1) can cause tumors in newborn rodents, with tumorigenicity related to the presence of a unique space
281 cells, and provide a mechanistic link among tumorigenicity, sorafenib resistance, and glucose metabo
282 UC1-C decreases PC self-renewal capacity and tumorigenicity, suggesting a potential therapeutic appro
283 to be ganglioside deficient exhibit impaired tumorigenicity, supporting a link between ganglioside-de
284 Those findings are here extended to in vivo tumorigenicity testing by employing orthotopic xenotrans
285 ESA(hi)PROCR(hi)SSEA-3(+) markers had higher tumorigenicity than those with conventional markers in v
286 12(R) had faster proliferation with stronger tumorigenicity that was caused by the reactivated KIT ki
287 We here report that EMT confers efficient tumorigenicity to murine breast cancer cells by the upre
289 s deprived of nutrients but suppressed their tumorigenicity, together suggesting the cancer cells ent
293 r verify the importance of heme in promoting tumorigenicity, we generated NSCLC cell lines with incre
294 h a significant growth delay and the loss of tumorigenicity when 10(4) cells were injected into mice.
296 RSPO2 suppresses CRC cell proliferation and tumorigenicity, whereas the depletion of RSPO2 enhances
297 cks its proteasomal destruction and enhances tumorigenicity, which could be reversed by Usp9x knockdo
298 h factor receptor) marks cells with enriched tumorigenicity, which would compel their specific target
299 to a striking inhibition of EGFRvIII-induced tumorigenicity, while increasing EGFRwt or HB-EGF levels
300 ived cancer cells, with simultaneous loss of tumorigenicity, without the need to revert to an embryon